Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by EternalPonzion Feb 02, 2020 4:32pm
161 Views
Post# 30631464

RE:RE:Whoever has listened to Francine

RE:RE:Whoever has listened to Francine
Well then, you must have or had a lot of shares. Assumption: You had (have) 200,000 at an average cost of $2.00CDN, then yes your claim works. You sound defeated. Why do you resign yourself to the 'all is lost' outcome? If you truly believe odds are slim for comeback you should sell half and ride out the rest. If you originally bought and added perhaps added to with conviction then see it through to the bitter or fruitful end. Hurdles are: 1. Loss of confidence in management's ability to execute flawlessly from this point and hopefully to a successful launch, which is understandable, 2. Litigation - very likely at some point due to what could be a grave protocol error 3. American protectionism. Unfortunately, for some reason the FDA has an disproportionate say in overall 'world' acceptance of a drug, even though all countries should be able to decide on their own COA. Amarin has a huge incentive to lobby thru media or dare I say it to certain decision makers within the FDA to maintain their monopoly - which BTW is suppose to be illegal in the US. I would prefer to think that is not the case but my trust level in government entities is very low, 4. The manufacture of this drug is very risky. Acasti has one supplier, in France I believe, that is willing to take on the dangerous manufacturing process. An accident (explosion) could easily happen , it has before when acetone was involved. This accident possibility will always be present. Stock will take a significant hit if it ever happened. Hopefully this will never happen but the point is, it could.
Bullboard Posts